Pathogenic germline variants in BRCA1 and BRCA2 (BRCA1/2) confer a cumulative risk for ovarian cancer by age 80 years of 44% and 17%, respectively.1 Other genes, including RAD51C, RAD51D, PALB2, BRIP1, and genes involved in DNA mismatch repair, are associated with a moderately increased risk of between 5% and 12%.2-5 In the absence of reliable early detection, prevention of ovarian cancer remains the most effective means to reduce disease impact, as the majority of patients have advanced-stage cancer at diagnosis, which is associated with high rates of relapse and mortality. This evidence concerns the gene PALB2 and ovarian cancer.